UBS downgraded AstraZeneca to Sell from Buy with a price target of 10,700 GBp, down from 13,000 GBp, after assuming coverage of the name. The company’s high exposure to U.S. Medicare Part D reform drives UBS’s estimates below consensus in 2025 and 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AIM ImmunoTech announces open enrollment for Phase 1b/2 study of Ampligen
- Absci appoints Sir Pangalos to its board of directors
- AstraZeneca put volume heavy and directionally bearish
- Compugen to receive $10M milestone payment from AstraZeneca
- Zura Bio names Robert Lisicki as COO, Kiran Nistala as CMO